First-Line Pembrolizumab vs Dabrafenib/Trametinib for BRAF V600–Mutant Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of the American Academy of Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
First-line pembrolizumab versus dabrafenib/trametinib treatment for BRAF V600-mutant advanced melanoma
J Am Acad Dermatol 2022 Sep 03;[EPub Ahead of Print], CG Kim, M Kim, J Hwang, ST Kim, M Jung, KH Kim, KH Kim, JS Chang, WS Koom, MR Roh, KY Chung, TM Kim, SK Kim, J Lee, SJ ShinFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.